Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the eff... और पढ़ें
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab ... और पढ़ें
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Dulaglutide on Re... और पढ़ें
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Re... और पढ़ें
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination W... और पढ़ें
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination W... और पढ़ें
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugat... और पढ़ें
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A randomised, double-blind, placebo-controlled trial with an open-label extension to assess the p... और पढ़ें
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection ... और पढ़ें
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 Study of a Selective AKT1 E17K Allosteric Inhibitor, ATV-1601, in Patients with Advance... और पढ़ें